Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -38.64% is 60% above its 5-year average of -96.40%, near the high end of its 5-year range (-568.58%–-25.65%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.88% above its 12-month average of -45.39%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -38.64%.
RETURN ON EQUITY (ROE)
-38.64%
RETURN ON EQUITY (ROE) AVG TTM
-45.39%
RETURN ON EQUITY (ROE) AVG 3Y
-91.64%
RETURN ON EQUITY (ROE) AVG 5Y
-96.40%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.88%
CURRENT VS 3Y AVG
+57.84%
CURRENT VS 5Y AVG
+59.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+8.03%
vs the sector median at left
Taysha Gene Therapies, Inc.
Market Cap
$1.41B
Return on Equity (ROE)
-38.64%
TTM Avg
-45.39%
3Y Avg
-91.64%
5Y Avg
-96.40%
Market Cap
$1.41B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Return on Equity (ROE)
N/A
TTM Avg
41.79%
3Y Avg
41.79%
5Y Avg
41.79%
Market Cap
$1.42B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
Market Cap
$1.39B
Return on Equity (ROE)
9.00%
TTM Avg
8.29%
3Y Avg
7.90%
5Y Avg
8.39%
Market Cap
$1.44B
Return on Equity (ROE)
N/A
TTM Avg
247.90%
3Y Avg
18.71%
5Y Avg
1.58%
Market Cap
$1.44B
Return on Equity (ROE)
23.70%
TTM Avg
9.74%
3Y Avg
8.98%
5Y Avg
11.20%
Market Cap
$1.38B
Return on Equity (ROE)
N/A
TTM Avg
-244.46%
3Y Avg
-323.47%
5Y Avg
-258.47%
Market Cap
$1.45B
Return on Equity (ROE)
-7.08%
TTM Avg
-0.64%
3Y Avg
-1.30%
5Y Avg
-2.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | $1.41B | -38.64% | -45.39% | -91.64% | -96.40% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.41B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | N/A | 41.79% | 41.79% | 41.79% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 1849.06% | -120.25% | -118.83% | -82.76% |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 9.00% | 8.29% | 7.90% | 8.39% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | 247.90% | 18.71% | 1.58% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 23.70% | 9.74% | 8.98% | 11.20% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.38B | N/A | -244.46% | -323.47% | -258.47% |
| Certara, Inc. (CERT)vs › | $1.45B | -7.08% | -0.64% | -1.30% | -2.08% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | -29.48% | -5.20% | -280.62% | -280.62% |
ROE
-38.6%
ROA
-31.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -38.64% |
| 2026-03-31 | -61.28% |
| 2025-12-31 | -44.14% |
| 2025-09-30 | -45.63% |
| 2025-06-30 | -37.28% |
| 2025-03-31 | -157.59% |
| 2024-12-31 | -124.85% |
| 2024-09-30 | -25.65% |
| 2024-06-30 | -105.02% |
| 2024-03-31 | -219.14% |
| 2023-12-31 | -148.88% |
| 2022-06-30 | -568.58% |
| 2022-03-31 | -380.12% |
| 2021-12-31 | -182.97% |
| 2021-09-30 | -101.47% |
| 2021-06-30 | -57.00% |
| 2021-03-31 | -38.86% |
| 2020-12-31 | -23.88% |
| 2020-09-30 | -15.99% |
